Tropical Journal of Pharmaceutical Research

Original Research Article | OPEN ACCESS

Role of catheter-directed DX9065a thrombolysis in the treatment of pulmonary embolism

Yi-Bai Xue

Department of Cardiac Surgery, The First Affiliated Hospital of Nanyang Medical College, Nanyang 473000, China;

For correspondence:- Email: xueyibai24@gmail.com Tel:+86-37763328308

Received: 3 March 2015 Accepted: 2 July 2015 Published: 30 August 2015

Citation: Xue Y. Role of catheter-directed DX9065a thrombolysis in the treatment of pulmonary embolism. Trop J Pharm Res 2015; 14(8):1475-1480 doi: 10.4314/tjpr.v14i8.21

© 2015 The authors.
This is an Open Access article that uses a funding model which does not charge readers or their institutions for access and distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0) and the Budapest Open Access Initiative (http://www.budapestopenaccessinitiative.org/read), which permit unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited..

Abstract

Purpose: To demonstrate the efficacy of low-dose DX9065a, catheter-directed ultrasound-accelerated thrombolysis (USAT) on the reversal of right ventricle RV dysfunction in patients with pulmonary embolism.

Methods: The analysis of 45 pulmonary embolism PE patients, aged 69 ± 13.5 years (range, 28 – 77 years) at intermediate- (n = 32) or high-risk (n = 13) was performed. The patients were treated with USAT and DX9065a (mean dose 35 ± 8.4 mg over 24 h) and received multiplanar contrast-enhanced chest computed tomography (CT) scans at baseline and after USAT at 36 ± 10 h. CT measurements were then performed.

Results: The results showed a significant decrease in the right to left ventricular dimension ratio (RV/LV ratio) from the baseline value of 1.42 ± 0.30 to 1.00 ± 0.02 at follow-up (p F6; 0.001). The modified Miller score showed that CT-angiographic pulmonary clot burden was also significantly reduced from 23.2 ± 4.7 to 6.2 ± 2.5 (p F6; 0.001). All the patients were discharged alive, and there were no systemic bleeding complications in any of them.

Conclusions: USAT and DX9065a, in low-dose, is a promising strategy for the reversal of right ventricular dilatation and reduction of pulmonary clot in patients with intermediate- and high-risk PE.

Keywords: Ultrasound accelerated (USAT), DX9065a, Ventricular dimension, Ventricular dilatation, Pulmonary clot, Clot burden, Pulmonary clot